Infectious complications of common interventional procedures_West China Medical Journal

Authors：

LI Yang ¹ ,  MAO Yiping ²

1. School of Nursing, Xuzhou Medical University, Xuzhou, Jiangsu 221004, P. R. China;
2. Infection Management Department, Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu 221000, P. R. China;

Corresponding?author：

MAO Yiping, Email: 385524376@qq.com

Keywords：

Interventional radiology; Interventional operation; Complication; Infection

DOI：

10.7507/1002-0179.201902023

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Interventional radiology (IR) has developed rapidly since its introduction into our country. More and more patients choose this minimally invasive procedure for treatment, but the incidence of infectious complications and potential mortality following IR procedures should not be underestimated. As the number and breadth of IR procedures grow, it becomes increasingly evident that interventional radiologists and infection control practitioners must possess a thorough understanding of these potential infectious complications and put more emphasis on the quality of care, so as to control the infections and expenses, and maximize the patient safety. This article reviews infectious complications associated with percutaneous ablation of liver tumors, transarterial embolization of liver tumors, percutaneous transhepatic cholangial drainage, and intravascular stents or grafts. Emphasis is placed on incidence, risk factors, and prevention. With the use of these strategies, IR procedures can be performed with reduced risk of infectious complications.

Citation： LI Yang, MAO Yiping. Infectious complications of common interventional procedures. West China Medical Journal, 2019, 34(3): 328-333. doi: 10.7507/1002-0179.201902023 Copy

1.	Margulis AR. Recent advances in clinical diagnostic radiology. 4. Interventional diagnostic roentgenology. Adv surg, 1971, 5: 88-102.
2.	朱海云, 程永德. 介入放射學抑或介入醫學. 介入放射學雜志, 2017, 26(7): 577-578.
3.	陳春林, 汪建新. 介入醫學的現狀和發展趨勢. 現代醫院, 2002, 2(1): 10-14.
4.	Cheikh A, Belefquih B, Chajai Y, et al. Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) colonization as a risk factor for developing ESBL infections in pediatric cardiac surgery patients: " retrospective cohort study”. BMC Infect Dis, 2017, 17(1): 237-242.
5.	張桂榮. 神經內科患者醫院感染影響因素的研究. 中國現代醫生, 2018, 56(9): 105-107.
6.	倪才方, 狄鎮海, 程永德. 介入放射科抗菌藥物使用指南 (草案). 介入放射學雜志, 2013, 22(5): 353-357.
7.	Moon E, Tam MD, Kikano RN, et al. Prophylactic antibiotic guidelines in modern interventional radiology practice. Semin Intervent Radiol, 2010, 27(4): 327-337.8.
8.	Venkatesan AM, Kundu S, Sacks D, et al. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. J Vasc Interv Radiol, 2010, 21(11): 1611-1630, quiz 1631.
9.	王芳軍. 影像學. 北京: 人民衛生出版社, 2012: 223-251.
10.	許茂盛. 醫學影像學. 北京: 清華大學出版社, 2012: 326-336.
11.	李彥豪, 何曉峰, 陳勇. 實用臨床介入診療學. 北京: 科學出版社, 2012: 1-133.
12.	石明濤, 余宇瀟, 趙開飛, 等. PTCD/PTBS 治療惡性梗阻性黃疸所致并發癥及其防治的研究進展. 海南醫學, 2018, 29(11): 1564-1567.
13.	成丕光, 王建強, 石天亭, 等. 梗阻性黃疸患者經皮肝穿膽道引流術后膽道感染的分析. 中華醫院感染學雜志, 2016, 26(12): 2753-2755.
14.	Liu JG, Wu J, Wang J, et al. Endoscopic biliary drainage versus percutaneous transhepatic biliary drainage in patients with resectable hilar cholangiocarcinoma: a systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A, 2018, 28(9): 1053-1060.
15.	Duan F, Cui L, Bai YH, et al. Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: a systematic review and meta-analysis. Cancer Imaging, 2017, 17(1): 27-33.
16.	李悅悅, 劉毅, 李艷君, 等. 101 例惡性梗阻性黃疸行經皮肝臟穿刺膽道引流術后膽道感染及抗感染治療分析. 藥學實踐雜志, 2016, 34(6): 556-559, 573.
17.	Lucatelli P, Corradini SG, Corona M, et al. Risk factors for Immediate and delayed-onset fever after percutaneous transhepatic biliary drainage. Cardiovasc Intervent Radiol, 2016, 39(5): 746-755.
18.	夏卿, 周新鋒, 范曉翔, 等. 梗阻性黃疸患者經皮經肝膽道引流術后膽道感染相關因素研究. 中華醫院感染學雜志, 2017, 27(17): 3960-3963.
19.	Xu C, Huang XE, Wang SX, et al. Comparison of infection between internal-external and external percutaneous transhepatic biliary drainage in treating patients with malignant obstructive jaundice. Asian Pac J Cancer Prev, 2015, 16(6): 2543-2546.
20.	Kiriyama S, Kozaka K, Takada T, et al. Tokyo guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci, 2018, 25(1): 17-30.
21.	中華醫學會外科學分會膽道外科學組. 急性膽道系統感染的診斷和治療指南(2011 版). 中華消化外科雜志, 2011, 10(1): 9-13.
22.	Ahn S, Lee YS, Lim KS, et al. Malignant biliary obstructions: can we predict immediate postprocedural cholangitis after percutaneous biliary drainage?. Support Care Cancer, 2013, 21(8): 2321-2326.
23.	陸霽, 蔡建珊, 孫強, 等. 良惡性梗阻性黃疸患者膽道感染的危險因素分析. 上海醫藥, 2018, 39(13): 27-30.
24.	謝興武, 唐先志, 吳鵬, 等. 經皮肝穿刺膽道引流術后膽道感染的主要病原菌類型及藥敏試驗分析. 中華介入放射學電子雜志, 2018, 6(4): 30-34.
25.	梁偉潮, 朱應昌, 韓福郎, 等. 膽道感染患者膽汁中病原菌的分布及對藥物的敏感性變化分析. 吉林醫學, 2018, 39(2): 301-303.
26.	Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci, 2018, 25(1): 3-16.
27.	Siriwardana RC, Niriella MA, Dassanayake AS, et al. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis-a prospective analysis. BMC Gastroenterol, 2015, 15: 96-101.
28.	姜敏霞, 陳旭高, 姚紅響. 肝癌肝動脈化療栓塞術后發生感染影響因素分析. 介入放射學雜志, 2018, 27(2): 133-136.
29.	Shin JU, Kim KM, Shin SW, et al. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. Digest Liver Dis, 2014, 46(9): 813-817.
30.	Lv WF, Lu D, He YS, et al. Liver abscess formation following transarterial chemoembolization clinical features, risk factors, bacteria spectrum, and percutaneous catheter drainage. Medicine, 2016, 95(17): e3503.
31.	Facciorusso A, Mariani L, Sposito C, et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol, 2016, 31(3): 645-653.
32.	周顏, 陳衛, 王小林, 等. 轉移性肝腫瘤 TACE 治療后肝膿腫形成的臨床特征及治療分析. 介入放射學雜志, 2018(1): 24-28.
33.	Rahimian J, Wilson T, Oram V, et al. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis, 2004, 39(11): 1654-1659.
34.	Woo S, Chung JW, Hur S, et al. Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol, 2013, 200(6): 1370-1377.
35.	Song SY, Chung JW, Han JK, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predispoding factors, and clinical outcome. J Vasc Interv Radiol, 2001, 12(3): 313-320.
36.	王燕玲, 何麗, 王燕燕, 等. 晚期肝癌患者 TACE 術后醫院感染病原菌與影響因素分析. 中華醫院感染學雜志, 2019, 29(4): 578-581.
37.	方欣, 黃昌拼, 解旭品, 等. 應用抗菌藥物預防血管介入治療患者感染的臨床研究. 中華醫院感染學雜志, 2014, 24(21): 5280-5281.
38.	Shelgikar CS, Loehle J, Scoggins CR, et al. Empiric antibioticsfor transarterial embolization in hepatocellular carcinoma: indicated?. J Surg Res, 2009, 151(1): 121-124.
39.	Brown DB, Cardella JF, Sacks D, et al. Quality improvementguidelines for transhepatic arterialchemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol, 2009, 20(7 Suppl): s219-s226.
40.	李光驍, 陳曉明. 射頻消融與微波消融治療肺腫瘤的對比研究. 臨床放射學雜志, 2017, 36(5): 724-727.
41.	Botsa EI, Thanou IL, Papatheodoropoulou AT, et al. Thermal ablation in the management of adrenal metastasis originating from non-small cell lung cancer: a 5-year single-center experience. Chin Med J, 2017, 130(17): 2027-2032.
42.	Healey TT, March BT, Baird G, et al. Microwave ablation for lung neoplasms: a retrospective analysis of long-term results. J Vasc Interv Radiol, 2017, 28(2): 206-211.
43.	Wah TM, Arellano RS, Gervais DA, et al. Image-guide percutaneous radiofrequency ablation syndrome: prospective survey. Radiology, 2005, 237(3): 1097-1102.
44.	Park JG, Park SY, Tak WY, et al. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,843 ablations in 1,211 patients in a single centre: experience over 10 years. Clin Radiol, 2017, 72(8): 692.e9-692.e15.
45.	Alexandre, Zanchenko, Fonseca, et al. Complications of radiofrequency ablation of hepatic tumors: frequency and risk factors. World J Hepatol, 2014, 6(3): 107-113.
46.	吳逢清, 汪秀云. 肝臟腫瘤患者射頻消融術治療后肝內感染的發生及其影響因素研究. 河北醫學, 2018, 24(4): 588-591.
47.	Francica G, Meloni MF, Riccardi L, et al. Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study. Eur J Radiol, 2018, 105: 96-101.
48.	李因茵, 于燕波, 劉澤, 等. 328 例原發性肝癌單點及多點微波消融術后并發癥的觀察與分析. 中華保健醫學雜志, 2018, 20(6): 464-466.
49.	Zheng AM, Wang XW, Yang X, et al. Major complications after lung microwave ablation: a single-center experience on 204 sessions. Ann Thorac Surg, 2014, 98(1): 243-248.
50.	Kashima M, Yamakado K, Takaki HA, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am J Roentgenol, 2011, 197(4): W576-W580.
51.	Mu L, Pan T, Lyu N, et al. CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium. Lung Cancer, 2018, 122: 25-31.
52.	Yang X, Ye X, Lin ZY, et al. Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity-lung adenocarcinoma: a pilot study. J Cancer Res Ther, 2018, 14(4): 764-771.
53.	Cadeddu JA, Jeffrey A. Re: percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. J Urol, 2013, 190(1): 63.
54.	Schmit GD, Schenck LA, Thompson R, et al. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology, 2014, 272(3): 903-910.
55.	Crawford D, van Sonnenberg E. Infectious outcomes from renal tumor ablation: prophylactic antibiotics or not?. Cardiovasc Intervent Radiol, 2018, 41(10): 1573-1578.
56.	郭芳, 李佳, 陳磊, 等. 超聲引導下經皮腎臟腫瘤射頻消融術的早期經驗. 腫瘤影像學, 2018, 27(4): 279-284.
57.	穆夢娟, 于杰, 梁萍, 等. 超聲引導經皮微波消融治療小腎癌的長期療效觀察. 南方醫科大學學報, 2016, 36(5): 622-627.
58.	韓玥. 經皮肝癌熱消融治療的并發癥及防治. 實用醫學雜志, 2013, 29(21): 3451-3453.
59.	Tajiri K, Baba H, Kawai K, et al. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. Gastroenterol Hepatol, 2016, 31(7): 1291-1299.
60.	侯繼野, 姜楊, 董延龍, 等. 肝臟腫瘤患者射頻消融術后感染相關并發癥及其臨床分析. 中華醫院感染學雜志, 2016, 26(22): 5163-5165.
61.	Huang SY, Philip A, Richter MD, et al. Prevention and management of infectious complications of percutaneous interventions. Semin Intervent Radiol, 2015, 32(2): 78-88.
62.	Lejay A, Koncar I, Diener H, et al. Post-operative Infection of prosthetic materials or stents involving the supra-aortic trunks: a comprehensive review. Eur J Vasc Endovasc Surg, 2018, 56(6): 885-900.
63.	Lai CH, Lin YK, Lee WL, et al. Coronary stent infection presented as recurrent stent thrombosis. Yonsei Med J, 2017, 58(2): 458-461.
64.	Hammami R, Avran A, Abid L, et al. Acute pericarditis and stent infection. Médecine et Maladies Infectieuses, 2016(46): 396-401.
65.	李晶晶, 武欣迎, 徐雋, 等. 預防使用抗菌藥物對冠狀動脈支架置入術后感染的影響. 醫藥導報, 2015, 34(9): 1227-1230.
66.	謝年謹, 羅淞元, 薛凌, 等. 預防性抗生素在導管室進行完全經皮穿刺主動脈覆膜支架植入術的應用. 南方醫科大學學報, 2015, 35(4): 578-582.
67.	Fatima J, Duncan AA, de Grandis E, et al. Treatment strategies and outcomes in patients with infected aortic endografts. J Vasc Surg, 2013, 58(2): 371-379.

1. Margulis AR. Recent advances in clinical diagnostic radiology. 4. Interventional diagnostic roentgenology. Adv surg, 1971, 5: 88-102.
2. 朱海云, 程永德. 介入放射學抑或介入醫學. 介入放射學雜志, 2017, 26(7): 577-578.
3. 陳春林, 汪建新. 介入醫學的現狀和發展趨勢. 現代醫院, 2002, 2(1): 10-14.
4. Cheikh A, Belefquih B, Chajai Y, et al. Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) colonization as a risk factor for developing ESBL infections in pediatric cardiac surgery patients: " retrospective cohort study”. BMC Infect Dis, 2017, 17(1): 237-242.
5. 張桂榮. 神經內科患者醫院感染影響因素的研究. 中國現代醫生, 2018, 56(9): 105-107.
6. 倪才方, 狄鎮海, 程永德. 介入放射科抗菌藥物使用指南 (草案). 介入放射學雜志, 2013, 22(5): 353-357.
7. Moon E, Tam MD, Kikano RN, et al. Prophylactic antibiotic guidelines in modern interventional radiology practice. Semin Intervent Radiol, 2010, 27(4): 327-337.8.
8. Venkatesan AM, Kundu S, Sacks D, et al. Practice guidelines for adult antibiotic prophylaxis during vascular and interventional radiology procedures. Written by the Standards of Practice Committee for the Society of Interventional Radiology and Endorsed by the Cardiovascular Interventional Radiological Society of Europe and Canadian Interventional Radiology Association [corrected]. J Vasc Interv Radiol, 2010, 21(11): 1611-1630, quiz 1631.
9. 王芳軍. 影像學. 北京: 人民衛生出版社, 2012: 223-251.
10. 許茂盛. 醫學影像學. 北京: 清華大學出版社, 2012: 326-336.
11. 李彥豪, 何曉峰, 陳勇. 實用臨床介入診療學. 北京: 科學出版社, 2012: 1-133.
12. 石明濤, 余宇瀟, 趙開飛, 等. PTCD/PTBS 治療惡性梗阻性黃疸所致并發癥及其防治的研究進展. 海南醫學, 2018, 29(11): 1564-1567.
13. 成丕光, 王建強, 石天亭, 等. 梗阻性黃疸患者經皮肝穿膽道引流術后膽道感染的分析. 中華醫院感染學雜志, 2016, 26(12): 2753-2755.
14. Liu JG, Wu J, Wang J, et al. Endoscopic biliary drainage versus percutaneous transhepatic biliary drainage in patients with resectable hilar cholangiocarcinoma: a systematic review and meta-analysis. J Laparoendosc Adv Surg Tech A, 2018, 28(9): 1053-1060.
15. Duan F, Cui L, Bai YH, et al. Comparison of efficacy and complications of endoscopic and percutaneous biliary drainage in malignant obstructive jaundice: a systematic review and meta-analysis. Cancer Imaging, 2017, 17(1): 27-33.
16. 李悅悅, 劉毅, 李艷君, 等. 101 例惡性梗阻性黃疸行經皮肝臟穿刺膽道引流術后膽道感染及抗感染治療分析. 藥學實踐雜志, 2016, 34(6): 556-559, 573.
17. Lucatelli P, Corradini SG, Corona M, et al. Risk factors for Immediate and delayed-onset fever after percutaneous transhepatic biliary drainage. Cardiovasc Intervent Radiol, 2016, 39(5): 746-755.
18. 夏卿, 周新鋒, 范曉翔, 等. 梗阻性黃疸患者經皮經肝膽道引流術后膽道感染相關因素研究. 中華醫院感染學雜志, 2017, 27(17): 3960-3963.
19. Xu C, Huang XE, Wang SX, et al. Comparison of infection between internal-external and external percutaneous transhepatic biliary drainage in treating patients with malignant obstructive jaundice. Asian Pac J Cancer Prev, 2015, 16(6): 2543-2546.
20. Kiriyama S, Kozaka K, Takada T, et al. Tokyo guidelines 2018: diagnostic criteria and severity grading of acute cholangitis (with videos). J Hepatobiliary Pancreat Sci, 2018, 25(1): 17-30.
21. 中華醫學會外科學分會膽道外科學組. 急性膽道系統感染的診斷和治療指南(2011 版). 中華消化外科雜志, 2011, 10(1): 9-13.
22. Ahn S, Lee YS, Lim KS, et al. Malignant biliary obstructions: can we predict immediate postprocedural cholangitis after percutaneous biliary drainage?. Support Care Cancer, 2013, 21(8): 2321-2326.
23. 陸霽, 蔡建珊, 孫強, 等. 良惡性梗阻性黃疸患者膽道感染的危險因素分析. 上海醫藥, 2018, 39(13): 27-30.
24. 謝興武, 唐先志, 吳鵬, 等. 經皮肝穿刺膽道引流術后膽道感染的主要病原菌類型及藥敏試驗分析. 中華介入放射學電子雜志, 2018, 6(4): 30-34.
25. 梁偉潮, 朱應昌, 韓福郎, 等. 膽道感染患者膽汁中病原菌的分布及對藥物的敏感性變化分析. 吉林醫學, 2018, 39(2): 301-303.
26. Gomi H, Solomkin JS, Schlossberg D, et al. Tokyo Guidelines 2018: antimicrobial therapy for acute cholangitis and cholecystitis. J Hepatobiliary Pancreat Sci, 2018, 25(1): 3-16.
27. Siriwardana RC, Niriella MA, Dassanayake AS, et al. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis-a prospective analysis. BMC Gastroenterol, 2015, 15: 96-101.
28. 姜敏霞, 陳旭高, 姚紅響. 肝癌肝動脈化療栓塞術后發生感染影響因素分析. 介入放射學雜志, 2018, 27(2): 133-136.
29. Shin JU, Kim KM, Shin SW, et al. A prediction model for liver abscess developing after transarterial chemoembolization in patients with hepatocellular carcinoma. Digest Liver Dis, 2014, 46(9): 813-817.
30. Lv WF, Lu D, He YS, et al. Liver abscess formation following transarterial chemoembolization clinical features, risk factors, bacteria spectrum, and percutaneous catheter drainage. Medicine, 2016, 95(17): e3503.
31. Facciorusso A, Mariani L, Sposito C, et al. Drug-eluting beads versus conventional chemoembolization for the treatment of unresectable hepatocellular carcinoma. J Gastroenterol Hepatol, 2016, 31(3): 645-653.
32. 周顏, 陳衛, 王小林, 等. 轉移性肝腫瘤 TACE 治療后肝膿腫形成的臨床特征及治療分析. 介入放射學雜志, 2018(1): 24-28.
33. Rahimian J, Wilson T, Oram V, et al. Pyogenic liver abscess: recent trends in etiology and mortality. Clin Infect Dis, 2004, 39(11): 1654-1659.
34. Woo S, Chung JW, Hur S, et al. Liver abscess after transarterial chemoembolization in patients with bilioenteric anastomosis: frequency and risk factors. AJR Am J Roentgenol, 2013, 200(6): 1370-1377.
35. Song SY, Chung JW, Han JK, et al. Liver abscess after transcatheter oily chemoembolization for hepatic tumors: incidence, predispoding factors, and clinical outcome. J Vasc Interv Radiol, 2001, 12(3): 313-320.
36. 王燕玲, 何麗, 王燕燕, 等. 晚期肝癌患者 TACE 術后醫院感染病原菌與影響因素分析. 中華醫院感染學雜志, 2019, 29(4): 578-581.
37. 方欣, 黃昌拼, 解旭品, 等. 應用抗菌藥物預防血管介入治療患者感染的臨床研究. 中華醫院感染學雜志, 2014, 24(21): 5280-5281.
38. Shelgikar CS, Loehle J, Scoggins CR, et al. Empiric antibioticsfor transarterial embolization in hepatocellular carcinoma: indicated?. J Surg Res, 2009, 151(1): 121-124.
39. Brown DB, Cardella JF, Sacks D, et al. Quality improvementguidelines for transhepatic arterialchemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. J Vasc Interv Radiol, 2009, 20(7 Suppl): s219-s226.
40. 李光驍, 陳曉明. 射頻消融與微波消融治療肺腫瘤的對比研究. 臨床放射學雜志, 2017, 36(5): 724-727.
41. Botsa EI, Thanou IL, Papatheodoropoulou AT, et al. Thermal ablation in the management of adrenal metastasis originating from non-small cell lung cancer: a 5-year single-center experience. Chin Med J, 2017, 130(17): 2027-2032.
42. Healey TT, March BT, Baird G, et al. Microwave ablation for lung neoplasms: a retrospective analysis of long-term results. J Vasc Interv Radiol, 2017, 28(2): 206-211.
43. Wah TM, Arellano RS, Gervais DA, et al. Image-guide percutaneous radiofrequency ablation syndrome: prospective survey. Radiology, 2005, 237(3): 1097-1102.
44. Park JG, Park SY, Tak WY, et al. Early complications after percutaneous radiofrequency ablation for hepatocellular carcinoma: an analysis of 1,843 ablations in 1,211 patients in a single centre: experience over 10 years. Clin Radiol, 2017, 72(8): 692.e9-692.e15.
45. Alexandre, Zanchenko, Fonseca, et al. Complications of radiofrequency ablation of hepatic tumors: frequency and risk factors. World J Hepatol, 2014, 6(3): 107-113.
46. 吳逢清, 汪秀云. 肝臟腫瘤患者射頻消融術治療后肝內感染的發生及其影響因素研究. 河北醫學, 2018, 24(4): 588-591.
47. Francica G, Meloni MF, Riccardi L, et al. Ablation treatment of primary and secondary liver tumors under contrast-enhanced ultrasound guidance in field practice of interventional ultrasound centers. A multicenter study. Eur J Radiol, 2018, 105: 96-101.
48. 李因茵, 于燕波, 劉澤, 等. 328 例原發性肝癌單點及多點微波消融術后并發癥的觀察與分析. 中華保健醫學雜志, 2018, 20(6): 464-466.
49. Zheng AM, Wang XW, Yang X, et al. Major complications after lung microwave ablation: a single-center experience on 204 sessions. Ann Thorac Surg, 2014, 98(1): 243-248.
50. Kashima M, Yamakado K, Takaki HA, et al. Complications after 1000 lung radiofrequency ablation sessions in 420 patients: a single center’s experiences. AJR Am J Roentgenol, 2011, 197(4): W576-W580.
51. Mu L, Pan T, Lyu N, et al. CT-guided percutaneous radiofrequency ablation for lung neoplasms adjacent to the pericardium. Lung Cancer, 2018, 122: 25-31.
52. Yang X, Ye X, Lin ZY, et al. Computed tomography-guided percutaneous microwave ablation for treatment of peripheral ground-glass opacity-lung adenocarcinoma: a pilot study. J Cancer Res Ther, 2018, 14(4): 764-771.
53. Cadeddu JA, Jeffrey A. Re: percutaneous ablation of renal masses measuring 3.0 cm and smaller: comparative local control and complications after radiofrequency ablation and cryoablation. J Urol, 2013, 190(1): 63.
54. Schmit GD, Schenck LA, Thompson R, et al. Predicting renal cryoablation complications: new risk score based on tumor size and location and patient history. Radiology, 2014, 272(3): 903-910.
55. Crawford D, van Sonnenberg E. Infectious outcomes from renal tumor ablation: prophylactic antibiotics or not?. Cardiovasc Intervent Radiol, 2018, 41(10): 1573-1578.
56. 郭芳, 李佳, 陳磊, 等. 超聲引導下經皮腎臟腫瘤射頻消融術的早期經驗. 腫瘤影像學, 2018, 27(4): 279-284.
57. 穆夢娟, 于杰, 梁萍, 等. 超聲引導經皮微波消融治療小腎癌的長期療效觀察. 南方醫科大學學報, 2016, 36(5): 622-627.
58. 韓玥. 經皮肝癌熱消融治療的并發癥及防治. 實用醫學雜志, 2013, 29(21): 3451-3453.
59. Tajiri K, Baba H, Kawai K, et al. Neutrophil-to-lymphocyte ratio predicts recurrence after radiofrequency ablation in hepatitis B virus infection. Gastroenterol Hepatol, 2016, 31(7): 1291-1299.
60. 侯繼野, 姜楊, 董延龍, 等. 肝臟腫瘤患者射頻消融術后感染相關并發癥及其臨床分析. 中華醫院感染學雜志, 2016, 26(22): 5163-5165.
61. Huang SY, Philip A, Richter MD, et al. Prevention and management of infectious complications of percutaneous interventions. Semin Intervent Radiol, 2015, 32(2): 78-88.
62. Lejay A, Koncar I, Diener H, et al. Post-operative Infection of prosthetic materials or stents involving the supra-aortic trunks: a comprehensive review. Eur J Vasc Endovasc Surg, 2018, 56(6): 885-900.
63. Lai CH, Lin YK, Lee WL, et al. Coronary stent infection presented as recurrent stent thrombosis. Yonsei Med J, 2017, 58(2): 458-461.
64. Hammami R, Avran A, Abid L, et al. Acute pericarditis and stent infection. Médecine et Maladies Infectieuses, 2016(46): 396-401.
65. 李晶晶, 武欣迎, 徐雋, 等. 預防使用抗菌藥物對冠狀動脈支架置入術后感染的影響. 醫藥導報, 2015, 34(9): 1227-1230.
66. 謝年謹, 羅淞元, 薛凌, 等. 預防性抗生素在導管室進行完全經皮穿刺主動脈覆膜支架植入術的應用. 南方醫科大學學報, 2015, 35(4): 578-582.
67. Fatima J, Duncan AA, de Grandis E, et al. Treatment strategies and outcomes in patients with infected aortic endografts. J Vasc Surg, 2013, 58(2): 371-379.

Previous Article
Progress of ventilator-associated events
Next Article
Utility of whole-genome sequencing in tracking healthcare associated infection outbreaks

West China Medical Journal

Infectious complications of common interventional procedures

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content